- Home
- ZLAB vs HRMY Comparison
ZLAB vs HRMY Comparison
Compare ZLAB & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZLAB | HRMY |
|---|---|---|
| Founded | 2013 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ZLAB | HRMY |
|---|---|---|
| Price | $17.59 | $39.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $57.22 | $51.33 |
| AVG Volume (30 Days) | ★ 827.4K | 789.9K |
| Earning Date | 11-06-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $441,629,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $30.20 | $23.11 |
| Revenue Next Year | $34.71 | $16.15 |
| P/E Ratio | ★ N/A | $12.79 |
| Revenue Growth | ★ 24.14 | 21.13 |
| 52 Week Low | $17.72 | $25.52 |
| 52 Week High | $44.34 | $40.93 |
Technical Indicators
Market Signals| Indicator | ZLAB | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 17.58 | 69.66 |
| Support Level | $19.40 | $38.12 |
| Resistance Level | $18.67 | $40.00 |
| Average True Range (ATR) | 0.50 | 1.24 |
| MACD | 0.07 | 0.15 |
| Stochastic Oscillator | 3.05 | 74.54 |
Price Performance
Historical ComparisonAbout ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.